All Stories

  1. Antiretroviral Treatment and Antihypertensive Therapy
  2. Does established vascular kidney disease exist?
  3. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease
  4. Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease
  5. PAIT-survey—Prevalence of albuminuria in patients with diabetes and hypertension in Turkey
  6. Lack of Correlation of Carotid Intima-Media Index and Peripheral Artery Disease
  7. J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?
  8. Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function
  9. Anemia as very late-onset cytomegalovirus disease after kidney transplantation
  10. J Curve is showed in CKD patients
  11. Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug
  12. INTERSTITIAL NEPHROPATHY REDUCES CISTATIN C CONCENTRATIONS
  13. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study
  14. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
  15. Dihydropyridine calcium channel blockers and renal disease
  16. Erythropoietin, chronic renal failure and cancer
  17. Eritropoyetina, insuficiencia renal crónica y cáncer
  18. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
  19. Non-Proteinuric Diabetic Nephropathy
  20. Cistatina C como predictor de mortalidad en población hipertensa de Extremadura
  21. Prevalencia del hiperparatiroidismo secundario en pacientes con enfermedad renal crónica estadios 3 y 4 atendidos en medicina interna
  22. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine
  23. Anemia ferropénica en los pacientes con insuficiencia renal crónica (IRC): influencia de la diabetes
  24. Cistatina C como signo de riesgo de enfermedad renal
  25. Cistatina C como predictor de mortalidad en la población hipertensa extremeña
  26. SP468DIABETES MELLITUS AND RENAL DISEASE: RESULTS OF A GENERAL POPULATION SURVEY IN SPAIN
  27. The H.U.G.E. formula (hematocrit, urea, sex) for screening chronic kidney disease (CKD) in an age-stratified general population
  28. Hypertension in the Elderly
  29. Beta-Blockers use for Hypertension in the Elderly
  30. Editorial (Thematic Issue: Antihypertensive Treatment in the Elderly)
  31. Enfermedad renal isquémica arteriosclerótica: retos clínicos
  32. Atherosclerotic ischemic renal disease: Clinical challenges
  33. Research update for articles published in EJCI in 2012
  34. Guías de hipertensión: Muchas y mal avenidas
  35. Uso de agentes estimuladores de la eritropoyesis en pacientes con insuficiencia cardiaca congestiva
  36. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: The red and the black
  37. Renin–Angiotensin System Blocking Drugs
  38. Use of α1-microglobulin for diagnosing chronic interstitial nephropathy
  39. Prevalence of obesity and associated cardiovascular risk: the DARIOS study
  40. Increased frequency of microalbuminuria in patients receiving statins
  41. Prevalence of abnormal urinary albumin excretion in elderly people: a Spanish survey
  42. Intensive treatment of persistent microalbuminuria: determinants of treatment resistance
  43. Características clínicas y mortalidad de la insuficiencia cardiaca. Estudio INCAex
  44. Blood Pressure in Renal Disease: Objectives, Surrogate Markers and Treatment
  45. ¿Es peligroso reducir excesivamente la presión arterial?: la curva J
  46. Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population
  47. Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study
  48. Blood Pressure in Renal Disease: How to Accomplish the Goal?
  49. A proposal for improving the KDIGO renal disease risk table
  50. Estimated Glomerular Filtration Rate from Serum Cystatin C: Significant Differences among Several Equations Results
  51. Hematocrit, urea and gender: The Hematocrit, Urea and GEnder formula for prognosing progressive renal failure in diabetic nephropathy
  52. La pro-renina y su receptor. Papel de la inhibición directa de la renina
  53. Glomerular filtration rate estimated from serum cystatin
  54. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification
  55. Symmetrical Ambulatory Arterial Stiffness Index: Relationship with Serum Cystatin C Levels
  56. The value of a formula including haematocrit, blood urea and gender (HUGE) as a screening test for chronic renal insufficiency
  57. Efectos de un consejo nutricional simple en pacientes de alto riesgo vascular
  58. La pro-renina y su receptor. Papel de la inhibición directa de la renina
  59. Hidden chronic renal insufficiency and cardiovascular events in patients with hypertension in a primary care center
  60. Cystatin c and blood pressure: Results of 24h ambulatory blood pressure monitoring
  61. HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201
  62. Edema agudo de pulmón no cardiogénico por hidroclorotiazida
  63. Symmetrical ambulatory arterial stiffness index: Relationship with microalbuminuria and renal function
  64. Alteraciones del metabolismo glucídico en el estudio de control de factores de riesgo de Extremadura (estudio COFRE)
  65. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs
  66. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome
  67. Cardiovascular Risk in Uremic Patients: Darkness after AURORA
  68. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
  69. Long-Term Antiproteinuric Effect of Dual Renin-Angiotensin System Blockade
  70. Control de la dislipemia y uso de hipolipemiantes en Extremadura: resultados del estudio de Control de Factores de Riesgo de Extremadura (Estudio COFRE)
  71. Dual renin–angiotensin system blockade: In patients with single functioning kidney and proteinuria
  72. Control de la dislipemia en pacientes diabéticos en Extremadura
  73. Episodios cardiovasculares en pacientes con insuficiencia renal oculta detectada mediante fórmulas de filtrado glomerular
  74. Dual renin-angiotensin system blockade: on the target
  75. Limitaciones de la automedición de la presión arterial
  76. Riesgo cardiovascular asociado a microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial
  77. Effectiveness of eprosartan in diabetic hypertensive patients
  78. Calcium Antagonists and Renal Failure Progression
  79. Papel de la cistatina C en la valoración de la función renal y su relación con el riesgo cardiovascular
  80. Do we need glomerular filtration rate calculation?
  81. Microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial: estudio de una cohorte de 979 pacientes
  82. Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure
  83. Medición de la presión arterial y principio de la incertidumbre
  84. Hyperhomocysteinemia in patients with mild chronic renal failure
  85. Estudio doble ciego de la eficacia y la seguridad de la combinación a dosis fija de 10mg de enalapril/20mg de nitrendipino en comparación con el incremento de dosis de amlodipino en pacientes con hipertensión esencial no controlada con 5mg de amlodipino
  86. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients
  87. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study
  88. Comparative Effects of Fosinopril and Irbesartan on Hematopoiesis in Essential Hypertensives
  89. Sympathetic Skin Response in Peritoneal Dialysis Patients
  90. Nighttime Blood Pressure Fall in Renal Disease Patients
  91. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: Influence of hormone replacement therapy
  92. Enfermedades renales prevenibles: de vuelta a la nefrología
  93. ACUTE EFFECT OF HEMODIALYSIS WITH POLYACRYLONITRILE MEMBRANE ON NERVE CONDUCTION VELOCITIES
  94. ACUTE EFFECT OF HEMODIALYSIS ON SYMPATHETIC SKIN RESPONSE
  95. Nefropatía IgA
  96. N. Roberto Robles
  97. N.R. Robles
  98. Variabilidad de la presión arterial y morbimortalidad cardiovascular
  99. Sympathetic skin response in hemodialysis
  100. Increased serum magnesium levels in hemodialysis patients might worsen dyslipemia.
  101. Membranous Glomerulonephritis after Kidney Transplantation and Urologic Complications
  102. Peritoneal Mucormycosis in a Patient Receiving Continuous Ambulatory Peritoneal Dialysis